The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,360
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,161
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase
Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B., Marshall, B., Chandler, P., Antonia, S. J., Burgess, R., et al. (2002) · Science · doi:10.1126/science.1073514 · Cited by 1,028
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Nguyen, N. T., Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., & Kishimoto, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014465107 · Cited by 685
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113873109 · Cited by 572
Capuron, L., Ravaud, A., Neveu, P. J., Miller, A. H., Maes, M., & Dantzer, R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000995 · Cited by 473
Takikawa, O., Kuroiwa, T., Yamazaki, F., & Kido, R. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77982-4 · Cited by 472
Wainwright, D. A., Balyasnikova, I. V., Chang, A. L., Ahmed, A. U., Moon, K.-S., Auffinger, B., Tobias, A. L., Han, Y., & Lesniak, M. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2130 · Cited by 472
Metz, R., DuHadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1872 · Cited by 467
Mellor, A. L., Baban, B., Chandler, P., Marshall, B., Jhaver, K., Hansen, A., Koni, P. A., Iwashima, M., & Munn, D. H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1652 · Cited by 455
Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice
Ball, H. J., Sanchez-Perez, A., Weiser, S., Austin, C. J. D., Astelbauer, F., Miu, J., McQuillan, J. A., Stocker, R., Jermiin, L. S., & Hunt, N. H. (2007) · Gene · doi:10.1016/j.gene.2007.04.010 · Cited by 434
The aryl hydrocarbon receptor: a perspective on potential roles in the immune system
Stevens, E. A., Mezrich, J. D., & Bradfield, C. A. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03054.x · Cited by 413
Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N., Yanaihara, N., Yamada, K., Takikawa, O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2671 · Cited by 390
Matteoli, G., Mazzini, E., Iliev, I. D., Mileti, E., Fallarino, F., Puccetti, P., Chieppa, M., & Rescigno, M. (2010) · Gut · doi:10.1136/gut.2009.185108 · Cited by 378
Théate, I., van Baren, N., Pilotte, L., Moulin, P., Larrieu, P., Renauld, J.-C., Hervé, C., Gutierrez-Roelens, I., Marbaix, E., Sempoux, C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0137 · Cited by 363
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336
Immune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325
Tumour–induced immune modulation of sentinel lymph nodes
Cochran, A. J., Huang, R.-R., Lee, J., Itakura, E., Leong, S. P. L., & Essner, R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1919 · Cited by 268
Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer
Suzuki, Y., Suda, T., Furuhashi, K., Suzuki, M., Fujie, M., Hahimoto, D., Nakamura, Y., Inui, N., Nakamura, H., & Chida, K. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.001 · Cited by 261
Kim, J. W., Nam, K. H., Ahn, S.-H., Park, D. J., Kim, H.-H., Kim, S. H., Chang, H., Lee, J.-O., Kim, Y. J., Lee, H. S., et al. (2016) · Gastric Cancer · doi:10.1007/s10120-014-0440-5 · Cited by 250
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., Takahashi, N., Terauchi, M., Nawa, A., Nomura, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603477 · Cited by 248
Huang, A., Fuchs, D., Widner, B., Glover, C., Henderson, D. C., & Allen-Mersh, T. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600336 · Cited by 241
Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma.
Ozaki, Y., Edelstein, M. P., & Duch, D. S. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1242 · Cited by 240
Ino, K., Yamamoto, E., Shibata, K., Kajiyama, H., Yoshida, N., Terauchi, M., Nawa, A., Nagasaka, T., Takikawa, O., & Kikkawa, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4144 · Cited by 239
Role of indoleamine 2,3-dioxygenase in health and disease
Yeung, A. W. S., Terentis, A. C., King, N. J. C., & Thomas, S. R. (2015) · Clinical Science · doi:10.1042/cs20140392 · Cited by 237
Inaba, T., Ino, K., Kajiyama, H., Yamamoto, E., Shibata, K., Nawa, A., Nagasaka, T., Akimoto, H., Takikawa, O., & Kikkawa, F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.07.015 · Cited by 216
Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients
Weinlich, G., Murr, C., Richardsen, L., Winkler, C., & Fuchs, D. (2007) · Dermatology · doi:10.1159/000096906 · Cited by 197
Guillonneau, C., Hill, M., Hubert, F.-X., Chiffoleau, E., Hervé, C., Li, X.-L., Heslan, M., Usal, C., Tesson, L., Ménoret, S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28801 · Cited by 192
Babcock, T. A., & Carlin, J. M. (2000) · Cytokine · doi:10.1006/cyto.1999.0661 · Cited by 178
Soliman, H. H., Jackson, E., Neuger, T., Dees, E. C., Harvey, R. D., Han, H., Ismail-Khan, R., Minton, S., Vahanian, N. N., Link, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2357 · Cited by 174
Brody, J. R., Costantino, C. L., Berger, A. C., Sato, T., Lisanti, M. P., Yeo, C. J., Emmons, R. V., & Witkiewicz, A. K. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8745 · Cited by 174
Riesenberg, R., Weiler, C., Spring, O., Eder, M., Buchner, A., Popp, T., Castro, M., Kammerer, R., Takikawa, O., Hatz, R. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0942 · Cited by 170
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
Pan, K., Wang, H., Chen, M.-S., Zhang, H.-K., Weng, D.-S., Zhou, J., Huang, W., Li, J.-J., Song, H.-F., & Xia, J.-C. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0395-1 · Cited by 169
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Lob, S., Konigsrainer, A., Schafer, R., Rammensee, H.-G., Opelz, G., & Terness, P. (2008) · Blood · doi:10.1182/blood-2007-10-116111 · Cited by 167
Astigiano, S., Morandi, B., Costa, R., Mastracci, L., D'Agostino, A., Ratto, G. B., Melioli, G., & Frumento, G. (2005) · Neoplasia · doi:10.1593/neo.04658 · Cited by 163
Chon, S. Y., Hassanain, H. H., & Gupta, S. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.29.17247 · Cited by 162
Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
Ferdinande, L., Decaestecker, C., Verset, L., Mathieu, A., Lopez, X. M., Negulescu, A.-M., Maerken, T. V., Salmon, I. J., Cuvelier, C. A., & Demetter, P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.513 · Cited by 153
Chen, J.-Y., Li, C., Kuo, C.-C., Tsai, K. K., Hou, M., & Hung, W.-C. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0410-1 · Cited by 148
Iversen, T. Z., Engell-Noerregaard, L., Ellebæk, E., Andersen, R. S., Larsen, S. K., Bjoern, J., Zeyher, C., Gouttefangeas, C., Thomsen, B. M., Holm, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1560 · Cited by 129
Dai, X., & Zhu, B. T. (2009) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2009.953604 · Cited by 128
Hoyo-Becerra, C., Schlaak, J., & Hermann, D. M. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.06.200 · Cited by 120
Exploring the mechanism of tryptophan 2,3-dioxygenase
Thackray, S. J., Mowat, C. G., & Chapman, S. K. (2008) · Biochemical Society Transactions · doi:10.1042/bst0361120 · Cited by 115
Folgiero, V., Goffredo, B. M., Filippini, P., Masetti, R., Bonanno, G., Caruso, R., Bertaina, V., Mastronuzzi, A., Gaspari, S., Zecca, M., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1504 · Cited by 114
CDllc + Cells Modulate Pulmonary Immune Responses by Production of Indoleamine 2,3-Dioxygenase
Swanson, K. A., Zheng, Y., Heidler, K. M., Mizobuchi, T., & Wilkes, D. S. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0268oc · Cited by 114
Chevolet, I., Speeckaert, R., Schreuer, M. S., Neyns, B., Krysko, O., Bachert, C., Hennart, B., Allorge, D., van Geel, N., Gele, M. V., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.982382 · Cited by 113
Self-citationSoliman, H. H., Rawal, B., Fulp, J., Lee, J., Lopez, A. S., Bui, M. M., Khalil, F. K., Antonia, S. J., Yfantis, H. G., Lee, D. H., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1393-y · Cited by 109
Chamuleau, M. E. D., van de Loosdrecht, A. A., Hess, C. J., Janssen, J. J. W. M., Zevenbergen, A., Delwel, R., Valk, P. J. M., Löwenberg, B., & Ossenkoppele, G. J. (2008) · Haematologica · doi:10.3324/haematol.13113 · Cited by 107
Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas
Mitsuka, K., Kawataki, T., Satoh, E., Asahara, T., Horikoshi, T., & Kinouchi, H. (2013) · Neurosurgery · doi:10.1227/neu.0b013e31828cf945 · Cited by 103
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
Speeckaert, R., Vermaelen, K., van Geel, N., Autier, P., Lambert, J., Haspeslagh, M., Gele, M. V., Thielemans, K., Neyns, B., Roche, N. A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.007 · Cited by 100
Self-citationJia, Y., Wang, H., Wang, Y., Wang, T., Wang, M., Ma, M., Duan, Y., Meng, X., & Liu, L. (2015) · International Journal of Cancer · doi:10.1002/ijc.29481 · Cited by 98
Corm, S., Berthon, C., Imbenotte, M., Biggio, V., Lhermitte, M., Dupont, C., Briche, I., & Quesnel, B. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.014 · Cited by 97
Takao, M., Okamoto, A., Nikaido, T., Urashima, M., Takakura, S., Saito, M., Saito, M., Okamoto, S., Takikawa, O., Sasaki, H., et al. (2007) · Oncology Reports · doi:10.3892/or.17.6.1333 · Cited by 97
Jacquemier, J. D., Bertucci, F., Finetti, P., Esterni, B., Charafe‐Jauffret, E., Thibult, M., Houvenaeghel, G. F., den Eynde, B. J. V., Birnbaum, D., Olive, D., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25979 · Cited by 96
Ferns, D. M., Kema, I. P., Buist, M. R., Nijman, H. W., Kenter, G. G., & Jordanova, E. S. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.981457 · Cited by 95
Immunoactivative role of indoleamine 2,3‐dioxygenase in human hepatocellular carcinoma
Ishio, T., Goto, S., Tahara, K., Toné, S., Kawano, K., & Kitano, S. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2003.03259.x · Cited by 91
A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA
Yen, M., Lin, C., Chen, Y., Huang, S.-S., Yang, H., Chang, C., Lei, H.-Y., & Lai, M.-D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1988 · Cited by 88
MacKenzie, C. R., Hadding, U., & Däubener, W. (1998) · The Journal of Infectious Diseases · doi:10.1086/515347 · Cited by 88
Ninomiya, S., Hara, T., Tsurumi, H., Hoshi, M., Kanemura, N., Goto, N., Kasahara, S., Shimizu, M., Ito, H., Saito, K., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1093-z · Cited by 87
Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer
Karanikas, V., Ζαμανάκου, Μ., Kerenidi, T., Dahabreh, J., Hevas, A., Nakou, M., Gourgoulianis, K. I., & Germenis, A. E. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.8.4446 · Cited by 86
Creelan, B., Antonia, S. J., Bepler, G., Garrett, T. J., Simon, G. R., & Soliman, H. H. (2013) · OncoImmunology · doi:10.4161/onci.23428 · Cited by 86
Novel Action of Indoleamine 2,3-Dioxygenase Attenuating Acute Lung Allograft Injury
Liu, H., Liu, L., Fletcher, B. S., & Visner, G. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200509-1413oc · Cited by 86
Chamuleau, M. E. D., van de Loosdrecht, A. A., Hess, C. J., Janssen, J. J. W. M., Zevenbergen, A., Delwel, R., Valk, P. J. M., Löwenberg, B., & Ossenkoppele, G. J. (2008) · Haematologica · doi:10.3324/haematol.13112 · Cited by 86
Moretti, S., Menicali, E., Voce, P., Morelli, S., Cantarelli, S., Sponziello, M., Colella, R., Fallarino, F., Orabona, C., Alunno, A., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3351 · Cited by 83
Zhai, L., Dey, M., Lauing, K. L., Gritsina, G., Kaur, R., Lukas, R. V., Nicholas, M. K., RADEMAKER, A. W., Dostal, C. R., McCusker, R. H., et al. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.06.018 · Cited by 82
Yu, J., Sun, J., Wang, S. E., Li, H., Cao, S., Cong, Y., Liu, J., & Ren, X. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/469135 · Cited by 76
Inaba, T., Ino, K., Kajiyama, H., Shibata, K., Yamamoto, E., Kondo, S., Umezu, T., Nawa, A., Takikawa, O., & Kikkawa, F. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.02.028 · Cited by 74
Yoshikawa, T., Hara, T., Tsurumi, H., Goto, N., Hoshi, M., Kitagawa, J., Kanemura, N., Kasahara, S., Ito, H., Takemura, M., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01393.x · Cited by 72
Choe, J., Yun, J. Y., Jeon, Y., Kim, S. H., Park, G., Huh, J. R., Oh, S., & Kim, J. E. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-335 · Cited by 72
Chevolet, I., Speeckaert, R., Haspeslagh, M., Neyns, B., Krüse, V., Schreuer, M. S., Gele, M. V., van Geel, N., & Brochez, L. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13100 · Cited by 71
Self-citationPrognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma
Urakawa, H., Nishida, Y., Nakashima, H., Shimoyama, Y., Nakamura, S., & Ishiguro, N. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9290-7 · Cited by 69
The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer
Gao, Y.-F., Peng, R., Li, J., Ding, Y., Zhang, X., Wu, X., Pan, Z., Wan, D.-S., Zeng, Y.-X., & Zhang, X. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-71 · Cited by 68
Chevolet, I., Speeckaert, R., Schreuer, M. S., Neyns, B., Krysko, O., Bachert, C., Gele, M. V., van Geel, N., & Brochez, L. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-014-0376-x · Cited by 66
Self-citationFerdinande, L., Demetter, P., Perez-Novo, C. A., Waeytens, A., Taildeman, J., Rottiers, I., Rottiers, P., Vos, M. D., & Cuvelier, C. A. (2008) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200802100205 · Cited by 63
Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas
Laimer, K., Troster, B., Kloss, F. R., Schäfer, G., Obrist, P., Perathoner, A., Laimer, J., Brandacher, G., Rasse, M., Margreiter, R., et al. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.03.007 · Cited by 55
Bjoern, J., Iversen, T. Z., Nitschke, N. J., Andersen, M. H., & Svane, I. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.010 · Cited by 55
Gibney, G. T., Hamid, O., Gangadhar, T. C., Lutzky, J., Olszanski, A. J., Gajewski, T. F., Chmielowski, B., Boasberg, P. D., Zhao, Y., Newton, R. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3010 · Cited by 52
Mabuchi, R., Hara, T., Matsumoto, T., Shibata, Y., Nakamura, N., Nakamura, H., Kitagawa, J., Kanemura, N., Goto, N., Shimizu, M., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1041388 · Cited by 47
The Human Indoleamine 2,3-Dioxygenase Gene and Related Human Genes
Murray, M. F. (2007) · Current Drug Metabolism · doi:10.2174/138920007780362509 · Cited by 46
Zhang, G., Liu, W., Zhang, L., Wang, J., Kuang, M.-H., Liu, P., Lin, Y., Dai, S., & Du, J. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/384726 · Cited by 46
Liu, X.-Q., Lu, K., Feng, L., Ding, M., Gao, J., Ge, X., & Wang, X. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.804917 · Cited by 45
Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma
de Jong, R. A., Kema, I. P., Boerma, A., Boezen, H. M., van der Want, J. J. L., Gooden, M. J. M., Hollema, H., & Nijman, H. W. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.05.034 · Cited by 44
Zhang, R., Liu, H., Li, F., Li, H., Yu, J., & Ren, X. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2837-0 · Cited by 42
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Newton, R. C., Schaub, R., Maleski, J. E., Leopold, L. H., & Gajewski, T. F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3025 · Cited by 40
Komrokji, R. S., Wei, S., Mailloux, A. W., Zhang, L., Padron, E., Sallman, D. A., Lancet, J. E., Tinsley, S., Nardelli, L. A., Pinilla-Ibarz, J. A., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.005 · Cited by 40
Huang, T., Yen, M., Lin, C., Weng, T., Chen, Y., Lin, C., & Lai, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02094.x · Cited by 34
Berthon, C., Fontenay, M., Corm, S., Briche, I., Allorge, D., Hennart, B., Lhermitte, M., & Quesnel, B. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.02.001 · Cited by 34
Sznurkowski, J. J., Żawrocki, A., Emerich, J., Sznurkowska, K., & Biernat, W. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.04.050 · Cited by 33
Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma
de Jong, R. A., Toppen, N. L., ten Hoor, K. A., Boezen, H. M., Kema, I. P., Hollema, H., & Nijman, H. W. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.12.416 · Cited by 25
Engin, A., Gonul, I., Engin, A., Karamercan, A., Sepici-Dinçel, A., & Dursun, A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i13.3592 · Cited by 23
Tryptophan catabolites regulate mucosal sensitization to ovalbumin in respiratory airways
Odemuyiwa, S. O., Ebeling, C., Duta, V., Abel, M., Puttagunta, L., Cravetchi, O. V., Majaesic, C. M., Vliagoftis, H., & Moqbel, R. (2008) · Allergy · doi:10.1111/j.1398-9995.2008.01809.x · Cited by 19
FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients
Ryan, M. A., Crow, J., Kahmke, R. R., Fisher, S. R., Su, Z., & Lee, W. T. (2014) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2014.08.009 · Cited by 16
Chevolet, I., Schreuer, M. S., Speeckaert, R., Neyns, B., Hoorens, I., van Geel, N., Krüse, V., Hennart, B., Allorge, D., Gele, M. V., et al. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000171 · Cited by 14
Self-citationNam, S. J., Kim, S., Paik, J. H., Kim, T. M., Heo, D. S., Kim, C. W., & Jeon, Y. K. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1117610 · Cited by 12
Komrokji, R. S., Wei, S., Mailloux, A. W., et al. (2014) · Blood · doi:10.1182/blood.v124.21.4653.4653 · Cited by 7
Cited by
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Breast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 863
Discovery of IDO1 Inhibitors: From Bench to Bedside
Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 558
The landscape of cancer cell line metabolism
Li, H., Ning, S., Ghandi, M., Kryukov, G. V., Gopal, S., Deik, A., Souza, A., Pierce, K., Keskula, P., Hernandez, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0404-8 · Cited by 525
NAD+ metabolism, stemness, the immune response, and cancer
Navas, L. E., & Carnero, A. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00354-w · Cited by 517
Metadata
- Authors
- Brochez, L., Chevolet, I., & Kruse, V.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 76
- Pages
- 167-182
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2595109242
- Cited by
- 270
- References
- 110
- FWCI
- 15.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.